<DOC>
	<DOC>NCT00344409</DOC>
	<brief_summary>To compare the effectiveness of KRN321 to placebo in the treatment of anemia in cancer patients receiving multi cycle platinum-containing chemotherapy</brief_summary>
	<brief_title>A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>patients diagnosed as lung or gynecological cancer patients receiving platinum containing chemotherapy written informed consent hemoglobin concentration less than 11 d/dL at enrollment life expectancy of more than 4 months hemolysis, gastrointestinal bleeding, postoperative bleeding iron deficiency megaloblastic anemia any primary hematological disorder that could cause anemia received &gt; 2 RBC transfusions with 4 weeks or any RBC transfusion within 2 weeks before randomization prior treatment with KRN321 received erythropoetin therapy within 8 weeks before treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer patients</keyword>
	<keyword>platinum containing chemotherapy</keyword>
</DOC>